Top 10 Building Product Stocks For 2014

Since the beginning of the year, fuel cell makers Plug Power Inc. (NASDAQ: PLUG) and FuelCell Energy Inc. (NASDAQ: FCEL) have posted share price gains of around 289% and 76%, respectively, with most of the spike coming since the middle of February. A year ago, Plug Power stock was trading at $0.25 on its way down to $0.15. The stock closed Monday night at $5.69, after peaking at $11.72 on March 10.

The story is roughly the same for FuelCell Energy. Shares traded at $0.97 a year ago and are up 150% since then, closing last night at $2.49, after peaking at $4.74 on March 10.

What is a fair value for these two hot stocks? We start with the belief that these stocks are (probably) worth somewhere between their 52-week lows and their 52-week highs. As earnings are still elusive, or will be low for the sake of growth, we’ll use revenue as a guidepost.

Plug Power posted 2013 revenues of $26.6 million and is forecast by Thomson Reuters to post sales of $65.0 million in 2014 and $116.3 million in 2015. Note that the consensus estimate is based on only two analysts’ forecasts. Is it conceivable that Plug Power’s 2014 revenues will be 144% higher than 2013 revenues — and that 2015 revenues will rise another 79%? That is what the consensus estimates say, so that is what we’ll use, but a word to the wise here.

Top 10 Building Product Stocks For 2014: PetroLogistics LP (PDH)

PetroLogistics LP owns and operates propane dehydrogenation (PDH) facility. The Company is located in the vicinity of the Houston Ship Channel. As of April 23, 2012, the Company had an annual production capacity of approximately 1.45 billion pounds of propylene. Its PDH facility uses a CATOFIN dehydrogenation technology pursuant to a fully-paid license from CB&I Lummus. It derives its sales from three different sources: propylene sales, hydrogen sales, and mixed stream of butane and butylenes (C4 mix stream) and heavier hydrocarbons (C5+ stream) sales.

Contracted Propylene Sales

The Company has propylene sales contracts with The Dow Chemical Company (Dow), Total Petrochemicals USA, Inc. (Total), and INEOS Olefins and Polymers USA (INEOS), each of which use the propylene it supplies in the acrylic acid, polypropylene and acrylonitrile plants. Effective January 1, 2012, it added BASF Corporation (BASF) and LyondellBasell Industries N.V. (LyondellBasell) as additional contracted customers. It delivers propylene to these customers through its integrated pipeline system, which connects its facility to the Dow and Total plants and the LyondellBasell system, and through interconnected third-party pipelines, which connect its facility to INEOS and BASF and to other potential propylene customers.

Spot-Market Propylene Sales

Through the Company�� integrated pipeline system, the Company accesses other consumers of propylene, which it is able to supply on a spot basis with its excess production capacity. It manages its contract and spot portfolio.

Hydrogen Gas Sales

As part of the PDH process, the Company produces commercial quantities of hydrogen. Hydrogen is consumed in refinery processes, including fuel desulphurization.

C4 Mix/C5+ Streams Sales

The Company produces commercial quantities of C4 mix/C5+ streams. It sells the C4 mix stream to specialty chemical consumers or refiners and these customers tran! sport the purchased volumes from its facility by truck. The C5+ stream, which is heavy in aromatics, is transported by its pipeline to a Kinder Morgan terminal, and then sold to Texas Aromatics for use in the chemical or gasoline markets.

The Company competes with Enterprise, Chevron Phillips, ExxonMobil Chemical, Shell Chemical, Flint Hills and the Williams Companies.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on PetroLogistics (NYSE: PDH  ) , whose recent revenue and earnings are plotted below.

Top 10 Building Product Stocks For 2014: FirstEnergy Corporation(FE)

Firstenergy Corp. operates as a diversified energy company. The company, through its subsidiaries and affiliates, involves in the generation, transmission, and distribution of electricity, as well as energy management and other energy-related services. It serves approximately 6 million customers within 67,000 square miles through 10 utility operating companies in Ohio, Pennsylvania, New Jersey, West Virginia and Maryland. The company was founded in 1996 and is headquartered in Akron, Ohio.

Advisors' Opinion:

• [By Justin Loiseau]

  As coal prices regain their competitive edge, investors should watch TECO Energy (NYSE: TE  ) , Great Plains Energy (NYSE: GXP  ) , and FirstEnergy (NYSE: FE  ) .

• [By Justin Loiseau]

  Cutting out coal
  FirstEnergy (NYSE: FE  ) announced this month that it plans to shutter two coal-fired power plants in Pennsylvania by October. Coal plants are no lightweights when it comes to capacity, and the closure will knock 2,080 MW (around 10%) off FirstEnergy's total generation capacity.

• [By Lu Wang]

  Exelon tumbled 9.6 percent to $31.34. The largest U.S. operator of nuclear reactors was cut to hold from buy at Deutsche Bank AG. FirstEnergy (FE) Corp. slid 8.5 percent to $39.01. The utility company was cut to neutral from outperform at Credit Suisse Group AG.

5 Best Rising Stocks To Own For 2014: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors' Opinion:

• [By MONEYMORNING.COM]

  Sarepta Therapeutics Inc. (Nasdaq: SRPT)is developing a drug for Duchenne muscular dystrophy (remember all those Jerry Lewis Telethons?). The CDC estimates the disease affects about one out of every 5,600 to 7,700 males age 5 to 24 in the United States. By age 24, about 9 out of 10 of the 58% still alive at age 24 are wheelchair-bound. Not a pretty picture.

Top 10 Building Product Stocks For 2014: Coach Inc (COH)

Coach, Inc. (Coach), incorporated in June 2000, is a marketer of fine accessories and gifts for women and men. Coach�� product offerings include women�� and men�� bag, accessories, business cases, footwear, wearables, jewelry, sunwear, travel bags, watches and fragrance. The Company operates in two segments: Direct-to-Consumer and Indirect. Accessories include women�� and men�� small leather goods, novelty accessories and women�� and men�� belts. Women�� small leather goods, which coordinate with its handbags, include money pieces, wristlets, and cosmetic cases. Men�� small leather goods consist primarily of wallets and card cases. Novelty accessories include time management and electronic accessories. Key rings and charms are also included in this category. Men�� handbag collections include business cases, computer bags, messenger-style bags and totes. Footwear is distributed through select Coach retail stores, coach.com and about 1,000 United States department stores. Wearables category is comprised of jackets, sweaters, gloves, hats and scarves, including both cold weather and fashion.

The Company�� Jewelry category is comprised of bangle bracelets, necklaces, rings and earrings offered in both sterling silver and non-precious metals. Marchon Eyewear, Inc. (Marchon) is the Coach�� eyewear licensee. Coach sunglasses are sold in Coach retail stores and coach.com, department stores, select sunglass retailers and optical retailers in major markets. The travel collections are comprised of luggage and related accessories, such as travel kits and valet trays. Movado Group, Inc. (Movado) is the Company�� watch licensee, which develops a collection of watches.

Estee Lauder Companies Inc. (Estee Lauder), through its subsidiary, Aramis Inc., is Coach�� fragrance licensee. Fragrance is distributed through Coach retail stores, coach.com and about 4,000 United States department stores and 500 international locations. Coach offers four women�� fragrance col! lections and one men�� fragrance. The women�� fragrance collections include eau de perfume spray, eau de toilette spray, purse spray, body lotion and body splashes.

Direct-to-Consumer Segment

The Direct-to-Consumer segment consists of channels that provide the Company with immediate, controlled access to consumers: Coach-operated stores in North America; Japan; Hong Kong, Macau, and mainland China, Taiwan, Singapore and the Internet. This segment represented approximately 89% of Coach�� total net sales during the fiscal year ended June 30, 2012 (fiscal 2012), with North American stores and the Internet, Coach Japan and Coach China contributing approximately 63%, 18% and 6% of total net sales, respectively. Coach stores are located in regional shopping centers and metropolitan areas throughout the United States and Canada. The retail stores carry an assortment of products. Its stores are located in locations, such as New York, Chicago, San Francisco and Toronto.

Coach�� factory stores serve as a means to sell manufactured-for-factory-store product, including factory exclusives, as well as discontinued and irregular inventory outside the retail channel. These stores operate under the Coach Factory name. Coach�� factory store design, visual presentations and customer service levels support. Coach views its Website as a key communications vehicle for the brand to promote traffic in Coach retail stores and department store locations. Its online store provides a showcase environment where consumers can browse through a selected offering of the latest styles and colors.

Coach Japan operates department store shop-in-shop locations and freestanding flagship, retail and factory stores, as well as an e-commerce Website. Flagship stores offer an assortment of Coach products that are located in select shopping districts throughout Japan. Coach China operates department store shop-in-shop locations, as well as freestanding flagship, retail and factory sto! res. Flag! ship stores, which offer an assortment of Coach products, are located in select shopping districts throughout Hong Kong and mainland China. Coach Singapore and Taiwan operate department store shop-in-shop locations as well as freestanding flagship, retail and factory stores. Flagship stores, which offer a range of assortment of Coach products, are located in select shopping districts in Singapore and Taiwan.

The Reed Krakoff brand represents New American luxury primarily for handbags, accessories and ready-to-wear. Reed Krakoff operates department store shop-in-shop locations, freestanding flagship stores, as well as an e-commerce Website at reedkrakoff.com. Flagship stores, which offer an assortment of Reed Krakoff products, are located in select shopping districts in the United States and Japan.

Indirect Segment

The Indirect segment represented approximately 11% of total net sales in fiscal 2012, with United States Wholesale and Coach International representing approximately 6% and 4% of total net sales, respectively. The Indirect segment also includes royalties earned on licensed product. U.S. Wholesale channel offers access to Coach products to consumers who prefer shopping at department stores. Coach products are also available on macys.com, dillards.com, bloomingdales.com, lordandtaylor.com, belk.com, vonmaur.com and nordstrom.com. Coach�� products are sold in approximately 990 wholesale locations in the United States and Canada. Its U.S. wholesale customers are Macy�� (including Bloomingdale��), Dillard��, Nordstrom, Lord & Taylor, Carson�� and Saks Fifth Avenue.

Coach International channel represents sales to international wholesale distributors and authorized retailers. Coach has developed relationships with a select group of distributors who sell Coach products through department stores and freestanding retail locations in over 20 countries. Coach�� network of international distributors serves various markets: South Korea, US & T! erritorie! s, Taiwan, Malaysia, Hong Kong, Mexico, Saudi Arabia, Thailand, Japan, Australia, Singapore, UAE, France, China, Macau, Indonesia, Kuwait, Bahamas, Aruba, Vietnam, New Zealand, Bahrain, India and Brazil.

Advisors' Opinion:

• [By George Acs]

  One of last week's earnings related selections played true to form and dropped decidedly after earnings were released. Coach (COH) rarely disappoints in its ability to display significant moves in either direction after earnings and in this case, the disappointment was just shy of the $52.50 strike price at which I had sold weekly puts. However, with the week now done and at its new lower price, I think Coach represents a good entry point for new shares. With its newest competitor, at least in the hearts of stock investors, Michael Kors (KORS) reporting earnings this week, there is a chance that Coach may drop if Kors reports better than expected numbers, as the expectation will be that it had done so at Coach's expense. For that reason, I might consider waiting until Tuesday morning before deciding whether to add Coach to the portfolio.

Top 10 Building Product Stocks For 2014: CIENA Corporation(CIEN)

Ciena Corporation provides equipment, software, and service solutions that support the transport, switching, aggregation, and management of voice, video, and data traffic on communications networks worldwide. Its product portfolio consists of packet-optical transport that includes optical transport solutions to increase network capacity and enable delivery of a broader mix of high-bandwidth services; and packet-optical switching, which comprise optical switching platforms incorporating multiservice and multi-protocol switching systems that enable automated optical infrastructures for the delivery of various enterprise and consumer-oriented network services. The company also offers carrier Ethernet solutions, including service delivery switches and service aggregation switches to support the access and aggregation tiers of communications networks, as well as to support wireless backhaul infrastructures and business data services; and software solutions to track individual s ervices across multiple product suites, facilitating planned network maintenance, outage detection, and identification of customers or services affected by network troubles. In addition, Ciena Corporation provides consulting and support services, such as project management, deployment, maintenance support, consulting, and training services, as well as network analysis, planning, design, optimization, and tuning. Its packet-optical transport, packet-optical switching, and carrier Ethernet solutions products are used individually or as part of an integrated solution in communications networks operated by communications service providers, cable operators, governments, enterprises, and other network operators. The company sells its communications networking solutions directly, as well as through strategic channel relationships. Ciena Corporation was founded in 1992 and is headquartered in Linthicum, Maryland.

Advisors' Opinion:

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Thursday’s session are Lululemon Athletica Inc.(LULU), Ciena Corp.(CIEN) and Facebook Inc.(FB)

Top 10 Building Product Stocks For 2014: Northern Dynasty Minerals Ltd (NAK)

Northern Dynasty Minerals Ltd. (Northern Dynasty) is engaged in the exploration of mineral properties. The Company holds 650 square miles of mineral claims in southwest Alaska, United States. As of December 31, 2011, the Company owned 50% interest in the Pebble Limited Partnership (the Pebble Partnership). The Pebble Partnership owns the Pebble Copper-Gold-Molybdenum Project (the Pebble Project). Its principal mineral property interest is located in Alaska, United States. The Pebble property (Pebble) is located in southwest Alaska, 19 miles (30 kilometers) from the villages of Iliamna and Newhalen, and approximately 200 miles (320 kilometers) southwest of the city of Anchorage. The Company�� wholly owned subsidiaries include 3537137 Canada Inc., Northern Dynasty Partnership and U5 Resources Inc. In December 2013, the Company announced that it has completed the re-acquired 100% ownership and control of the Pebble Partnership. Advisors' Opinion:

• [By Paul Ausick]

  Stocks on the move: Boise Inc. (NYSE: BZ) is up 26% at $12.55 following the company�� acquisition by Packaging Corporation of America Inc. (NYSE: PKG) for $12.55 a share ($1.28 billion). Omeros Corp. (NASDAQ: OMER) is up 68.2% at $8.56 following an analyst upgrade. Northern Dynasty Minerals Ltd. (NYSEArca: NAK) is down 33.3% at $1.48 following an announcement from Anglo American plc that it was withdrawing from a massive copper mining project in Alaska.

• [By Ben Kramer-Miller]

  This article is about Northern Dynasty Minerals (NAK). Northern Dynasty Minerals has a market capitalization of $190 million. It is a 50% owner of the Pebble Mine in Alaska.

• [By Rich Duprey]

  Canadian mineral exploration and development company Northern Dynasty Minerals (NYSEMKT: NAK  ) has approved an $80 million budget for 2013 to advance its Pebble project in Alaska.

Top 10 Building Product Stocks For 2014: Redrow PLC (RDW)

Redrow PLC is a United Kingdom-based company engaged in residential development, which includes mixed use development. The Company�� operations are primarily focused on house building. Its completed projects include Signature, In the City/Regeneration and Debut. The Company's land holdings consist of both a current and forward land bank. As of June 30, 2010, the current land bank consisted of 11,600 plots owned with planning and 1,570 contracted plots, and its forward lank bank stood at around 22,000 plots. Its subsidiaries include Redrow Homes (Scotland) Ltd, Redrow Homes (Yorkshire) Ltd, Redrow Homes (Lancashire) Ltd, Redrow plc & Redrow Homes (NW) Ltd, Redrow Homes (Midlands) Ltd, Redrow Homes (South Midlands) Ltd, Redrow Homes (South West) Ltd, Redrow Homes (South Wales) Ltd and Redrow Homes (Eastern) Ltd. Advisors' Opinion:

• [By Namitha Jagadeesh]

  Redrow Plc (RDW) rallied 3.2 percent to 245.6 pence as Deutsche Bank AG increased its 12-month share-price estimate and profit forecasts for 2013 and 2014. The U.K. builder yesterday jumped the most in five months after saying pretax profit for the year ended June will beat analysts��estimates.

Top 10 Building Product Stocks For 2014: Kayne Anderson Energy Total Return Fund Inc (KYE)

Kayne Anderson Energy Total Return Fund, Inc. (the Fund) is a non-diversified closed-end investment company. The Fund�� investment objective is to obtain a high total return with an emphasis on current income. The Fund seeks to achieve this objective by investing primarily in securities of companies engaged in the energy industry, principally including publicly-traded energy-related master limited partnerships and limited liability companies taxed as partnerships (MLPs), MLP affiliates, energy-related United States and Canadian royalty trusts and income trusts and other companies that derive at least 50% of their revenues from operating assets used in, or providing energy-related services for, the exploration, development, production, gathering, transportation, processing, storing, refining, distribution, mining or marketing of natural gas, natural gas liquids (including propane), crude oil, refined petroleum products or coal.

Effective December 31, 2006, Kayne Anderson assigned the Investment Management Agreement to its subsidiary, KA Fund Advisors, LLC (the Adviser). The Fund focuses on investing at least 80% of the aggregate of its net assets and borrowings (total assets) in securities of Energy Companies. The Fund invests in equity securities, such as common stocks, preferred stocks, convertible securities, warrants, depository receipts, and equity interests in MLPs, MLP affiliates, royalty trusts and other Energy Companies.

Advisors' Opinion:

• [By Robert Rapier]

  We got several questions about Kayne Anderson Energy Total Return Fund (NYSE: KYE) during the chat. The main advantage of closed-end MLP funds is the diversification they provide, along with the convenience of a 1099 miscellaneous income tax form instead of having to deal with K-1 forms from each individual MLP. This makes a closed-end MLP fund a more attractive option for an IRA.

Top 10 Building Product Stocks For 2014: TESARO Inc (TSRO)

TESARO, Inc. (TESARO), incorporated in March 2010, is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�� marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells.

Rolapitant

Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). It is in Phase III clinical trials. CINV, if not prevented by prophylaxis, has the potential to afflict up to 90% or more of cancer patients undergoing chemotherapy, depending upon the type of chemotherapy administered the dosing schedule of the chemotherapy, and the patients' age and gender, among other predisposing factors. Prolonged nausea and vomiting may result in unwanted weight loss, dehydration and malnutrition, as well as hospitalization. The Company has in-licensed the rights to rolapitant from OPKO Health, Inc.

TSR-011

TSR-011 is an orally available ALK inhibitor in preclinical development. ALK is known to be involved in certain types of cancers, including subsets of NSCLC, neuroblastoma and lymphoma. For patients in these subsets, the ALK gene is fused to an activating partner or contains point mutations, resulting in constitutive activation of ALK and the growth of cancer cells and tumor development. Inhibition of ALK in these cancer cells results in cell death and tumor growth inhibition or regression. In August 2011, the United States Food and Drug Administration approved the first ALK inhibitor, developed by Pfizer Inc., Xalkori (crizotinib), which was approved for the treatment of patients with locally advanced or metastatic NSCLC that are ALK positive.

The Company competes with GlaxoSmithKline plc, Roche Holding Ltd! . and Sanofi S.A.

Advisors' Opinion:

• [By Brian Orelli]

  Tesaro (NASDAQ: TSRO  ) is also up today after announcing that it established a partnership with clinicians to run the phase 3 development of its PARP inhibitor, niraparib. The trial will enroll about 300 breast cancer patients with BRCA mutations, comparing niraparib to investigators' choice of other breast cancer treatments.

• [By Keith Speights]

  Positive response
  Clovis wasn't the only company to bring good news about an ovarian cancer drug to ASCO. TESARO� (NASDAQ: TSRO  ) announced phase 1 results for�niraparib. Shares of the biotech jumped 16% for the week.

Top 10 Building Product Stocks For 2014: Baoye Group Co Ltd (BKG)

Baoye Group Company Limited is engaged in the provision of construction service, manufacture and distribution of building materials and development and sale of properties. The Company three segments: construction, which includes provision of construction services; property development, which includes development and sale of properties, and building materials, which includes manufacture and distribution of building materials. Its subsidiaries include Zhejiang Baoye Construction Group Co., Ltd., Zhejiang Baoye Curtain Wall Decoration Co., Ltd., Zhejiang Baoye Infrastructure Construction Co., Ltd., Zhejiang Guangyi Construction and Decoration Co., Ltd., Zhejiang Baoye Real Estate Group Co., Ltd., Shaoxing Baoye Four Seasons Garden Real Estate Co., Ltd., Zhejiang Baoye Building Materials Industrialisation Co., Ltd., Zhejiang Baoye Steel Structure Co., Ltd. and others. During the year ended 31 December 2011, the Company acquired three parcels of new land in Wuhan, Shanghai, and Henan. Advisors' Opinion:

• [By Inyoung Hwang]

  Berkeley Group Holdings Plc (BKG) surged 8.3 percent after saying first-half profit rose 22 percent. London Stock Exchange Group Plc (LSE) climbed 2.4 percent after Bank of America Corp.�� Merrill Lynch unit recommended buying the stock. Givaudan SA (GIVN) lost 1.3 percent after Nestle SA said it will sell $1.27 billion of shares in the world�� largest flavorings maker.